Huaizhang Shi

Huaizhang Shi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in Brain Research Bulletin
Verified
Journal Article
Open access
JYJinshuo Yang
Jinshuo Yang
QWQiaowei Wu
Qiaowei Wu
SLShuai Lan
Shuai Lan
KYKaikun Yuan
Kaikun Yuan
BSBowen Sun
Bowen Sun
HSHuaizhang Shi
Huaizhang Shi
Following subarachnoid haemorrhage (SAH), excessive activation of oxidative stress and cell apoptosis plays a critical role in early brain injury (EBI). Peroxiredoxin-5 (Prdx5), predominantly expressed in neuronal mitochondria, acts as an antioxidant. However, the role of Prdx5 in EBI after SAH remains unclear. This study aims to elucidate the antioxidative stress and anti-apoptotic effects of Prdx5 in rats following SAH. In this study, an SAH model was established in Sprague-Dawley rats using endovascular perforation. Recombinant Prdx5 (rPrdx5) was administered intraperitoneally to upregulate Prdx5 expression after SAH in rats. Prdx5 small interfering RNA (Prdx5 siRNA) was administered prior to SAH modelling. The neuroprotective effects of Prdx5 were validated through SAH grading, brain water content, blood-brain barrier permeability, neurobehavioral tests, immunofluorescence, TUNEL staining, and Western blotting. The expression levels of endogenous Prdx5 significantly decreased after SAH. Treatment with rPrdx5 improved both short-term and long-term behaviour in rats, reduced brain water content and blood-brain barrier permeability, and exhibited anti-oxidative stress and anti-apoptotic effects. Measurements of oxidative stress-related indicators, including MDA, GSH-Px, SOD, and GSH/GSSG, confirmed that Prdx5 can alleviate oxidative stress in rats after SAH. Western blot analysis showed that rPrdx5 significantly increased the expression of Bcl-XL and Bcl-2 and reduced the expression of Bax and Cleaved Caspase-3, thereby exerting anti-apoptotic effects. Additionally, Prdx5 siRNA reversed the neuroprotective effects of rPrdx5, exacerbated neuronal damage and blood-brain barrier permeability, and increased levels of oxidative stress and apoptosis. In conclusion, our study demonstrated that specifically upregulating the expression of Prdx5 can reduce oxidative stress and apoptosis in rats after SAH, while also improving both short-term and long-term neurological impairments. Prdx5 is primarily expressed in the mitochondria of neuronal cells and is a crucial target for reducing ROS after SAH. rPrdx5 treatment may offer a promising therapeutic approach for clinical SAH patients.

12 October 2021 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
YWYabing Wang
Yabing Wang
TWTao Wang
Tao Wang
Adam DmytriwAdam Dmytriw
Adam Dmytriw
KYKun Yang
Kun Yang
LJLiqun Jiao
Liqun Jiao
OZOsama O Zaidat
Osama O Zaidat
Introduction The safety outcomes of endovascular therapy for intracranial artery stenosis in a real-world stetting are largely unknown. The Clinical Registration Trial of Intracranial Stenting for Patients with Symptomatic Intracranial Artery Stenosis (CRTICAS) was a prospective, multicentre, real-world registry designed to assess these outcomes and the impact of centre experience. Methods 1140 severe, symptomatic intracranial arterial stenosis (ICAS) patients treated with endovascular therapy were included from 26 centres, further divided into three groups according to the annual centre volume of intracranial angioplasty and stent placement procedures over 2 years: (1) high volume for ≥25 cases/year; (2) moderate volume for 10–25 cases/year and (3) low volume for <10 cases/year. Results The rate of 30-day stroke, transient ischaemic attack or death was 9.7% (111), with 5.4%, 21.1% and 9.7% in high-volume, moderate-volume and low-volume centres, respectively (p<0.05). Multivariable logistic regression confirmed high-volume centres had a significantly lower primary endpoint compared with moderate-volume centres (OR=0.187, 95% CI: 0.056 to 0.627; p≤0.0001), while moderate-volume and low-volume centres showed no significant difference (p=0.8456). Conclusion Compared with the preceding randomised controlled trials, this real-world, prospective, multicentre registry shows a lower complication rate of endovascular treatment for symptomatic ICAS. Non-uniform utilisation in endovascular technology, institutional experience and patient selection in different volumes of centres may have an impact on overall safety of this treatment.

4 October 2024 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JYJinshuo Yang
Jinshuo Yang
QWQiaowei Wu
Qiaowei Wu
YLYuchen Li
Yuchen Li
YZYongzhi Zhang
Yongzhi Zhang
SLShuai Lan
Shuai Lan
HSHuaizhang Shi
Huaizhang Shi

14 December 2023 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
LZLiang Zou
Liang Zou
SXShancai Xu
Shancai Xu
CWChunlei Wang
Chunlei Wang
PWPei Wu
Pei Wu
CXChao Xu
Chao Xu
HSHuaizhang Shi
Huaizhang Shi

30 August 2024 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
JYJinbiao Yao
Jinbiao Yao
BZBingjie Zheng
Bingjie Zheng
QSQi Sun
Qi Sun
FZFeifan Zhang
Feifan Zhang
ZJZhiyong Ji
Zhiyong Ji
HSHuaizhang Shi
Huaizhang Shi

22 April 2025 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
ZYZhonghui Yang
Zhonghui Yang
GZGuang Zhang
Guang Zhang
QWQiaowei Wu
Qiaowei Wu
YZYujing Zhu
Yujing Zhu
SXShancai Xu
Shancai Xu
HSHuaizhang Shi
Huaizhang Shi
Background and purpose: Tandem occlusion is a significant risk factor for poor outcomes following intravenous thrombolysis. The necessity of bridging therapy [intravenous thrombolysis prior to mechanical thrombectomy (MT)] for patients with tandem occlusion remains controversial. This study assessed the safety and efficacy of direct MT vs. bridging therapy in patients with tandem occlusions in the anterior circulation.Methods: This retrospective study enrolled patients with anterior circulation tandem occlusions treated with either direct mechanical thrombectomy (MT-alone group) or intravenous alteplase thrombolysis followed by MT (bridging group) between January 2019 and March 2022. The primary outcome was prespecified as a favorable outcome [modified Rankin Scale (mRS) score of 0–2] at 90 days. Secondary outcomes included successful reperfusion, overall mortality at 90 days, and rates of symptomatic intracranial hemorrhage (SICH) and asymptomatic intracranial hemorrhage (aSICH).Results: A total of 110 patients were enrolled, with 49 in the MT-alone group and 61 in the bridging group. A favorable outcome (mRS score of 0–2) at 90 days was achieved in 25 patients (51.0%) in the MT-alone group and in 34 patients (55.7%) in the bridging group, showing no significant difference between the groups, with an adjusted odds ratio (aOR) of 1.17 (95% CI, 0.47–2.90; P = 0.743). The incidence of aSICH was higher in the bridging group than in the MT-alone group [31.1% vs. 14.3%; aOR, 2.86 (95% CI, 1.04–7.88); P = 0.042]. Rates of successful reperfusion, overall mortality at 90 days, and SICH were similar between the groups. Multivariate analysis showed that a lower baseline National Institutes of Health Stroke Scale (NIHSS) score (P = 0.005), intraprocedural tirofiban administration (P = 0.012), and internal carotid artery stent implantation (P = 0.040) were associated with a favorable outcome at 90 days.Conclusion: This study found no evidence that prior intravenous thrombolysis affects clinical or imaging outcomes in patients with acute ischemic stroke due to anterior circulation tandem occlusions after endovascular thrombectomy. Bridging therapy may be associated with an increased rate of aSICH. Intraprocedural tirofiban administration, stent implantation, and a lower baseline NIHSS score were associated with favorable outcomes.